London, United Kingdom (PressExposure) July 05, 2011 -- GlobalData estimates that the global malignant mesothelioma therapeutics market was valued at $156m in 2010 and is forecast to grow at a compound annual growth rate (CAGR) of 3.9% to reach $204m by 2017. Much of this growth will follow the expected launch of NGR-hTNF in 2014. The existing malignant mesothelioma therapeutics market is dominated by the single treatment option, Alimta, which is a folate antimetabolite.
The malignant mesothelioma therapeutics market is relatively small as compared to other cancer markets due to the small patient pool. Despite this, untapped opportunities exist for drugs offering increased progression free survival (PFS) and improved safety profiles. Current competition in the global malignant mesothelioma therapeutics market is weak. There is only one approved chemotherapeutic regimen, Alimta in combination with cisplatin, which is the standard first line therapy. There is no second line treatment option available for this disease.
This disease mainly occurs in the later stage of life making drug tolerance an important criterion in selection of treatment regimens. The standard treatment option, Alimta, alters haemotological parameters such as thrombocytopenia, neutropenia and thus has a low safety profile.
The malignant mesothelioma pipeline is strong with the molecules having novel mechanisms of action. These pipeline molecules have shown better safety and efficacy results in their respective clinical trials. For example, NGR-hTNF, did not exhibit grade 3-4 toxicity, with grade 1-2 chills observed in the first infusions of the trial.
For Sample Pages, please click or add the below link to your browser: http://www.globaldata.com/reportstore/RequestSamplePages.aspx?ID=Malignant-Mesothelioma-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2017&CompanyID=PEXPO
These molecules, therefore, have the potential to change the future therapeutic landscape of malignant mesothelioma and provide a unique treatment opportunity. Molecules in the Phase III include NGR-Htnf, Onconase, Zolinza (vorinostat), thalidomide and Avastin (bevacizumab).
GlobalData's analysis indicates that the unmet need for malignant mesothelioma treatment is high due to lack of effective and tolerable treatments. The current drug regimen used in the treatment of malignant mesothelioma offers moderate efficacy with a low safety profile. Thus, there is a need for novel drugs that can treat the underlying cause of the disease. The malignant mesothelioma pipeline is strong with several molecules being first-in-class. These first-in-class molecules have distinct advantages over currently used products in terms of improved progression free survival, efficacy and safety profiles.
GlobalData, the industry analysis specialist, has released its new report, "Malignant Mesothelioma Therapeutics - Pipeline Assessment and Market Forecasts to 2017". The report is an essential source of information and analysis on the global malignant mesothelioma therapeutics market. The report identifies the key trends shaping and driving the global malignant mesothelioma therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global malignant mesothelioma therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
For further details, please click or add the below link to your browser: http://www.globaldata.com/reportstore/Report.aspx?ID=Malignant-Mesothelioma-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2017&CompanyID=PEXPO
Visit our report store: http://www.globaldata.com/reportstore
For more details contact:
North America: +1 646 395 5477
Europe: +44 207 753 4299
+44 1204 543 533
Asia Pacific: +91 40 6616 6782